Belumosudil is an oral selective rho-associated coiled-coil–containing protein kinase-2 (ROCK2) inhibitor. ROCK2 has been shown to be activated in a Th17-skewed milieu, leading to the upregulation of ...

Belumosudil, a small molecule inhibitor of the ROCK2 signaling pathway, is for the treatment of adult and pediatric patients with cGVHD after failure of at least two prior lines of systemic therapy.

Belumosudil (KD025) is a selective oral inhibitor of Rho-associated coiled-coil kinase 2, a signaling pathway that modulates inflammatory response and pro-fibrotic processes.

About Belumosudil Belumosudil (KD025) is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates inflammatory response and pro-fibrotic processes.

About Belumosudil (KD025) Belumosudil (KD025) is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates inflammatory response.

Belumosudil is indicated for the treatment of patients aged 12 years and older with cGVHD who have received at least two prior lines of systemic therapy. Belumosudil is the first approved therapy ...

Amber Specialty Pharmacy will begin dispensing Rezurock (belumosudil) tablets for chronic graft-versus-host disease, or cGVHD to patients throughout the United States. Rezurock is manufactured by ...

Belumosudil (KD025) is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates inflammatory response and pro-fibrotic processes.

announces positive topline results of pivotal trial of belumosudil (kd025) in chronic graft-versus-host disease Skip to main content Exclusive news, data and analytics for financial market ...

The rho-associated coiled-coil–containing protein kinase-2 (ROCK2) signaling pathway regulates the Th17/regulatory T cells balance and controls profibrotic pathways. Selective ROCK2 inhibition with ...